Aptose Biosciences (APTO) Downgraded by Zacks Investment Research to “Sell”
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Other analysts also recently issued research reports about the company. HC Wainwright set a $4.00 price objective on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. ValuEngine downgraded Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Roth Capital reaffirmed a “buy” rating and set a $5.00 price objective on shares of Aptose Biosciences in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $7.00 price objective on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Aptose Biosciences has an average rating of “Hold” and a consensus target price of $5.00.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. equities analysts forecast that Aptose Biosciences will post -0.61 EPS for the current fiscal year.
An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC boosted its position in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent reporting period. 0.81% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Aptose Biosciences (APTO) Downgraded by Zacks Investment Research to “Sell”” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/01/18/aptose-biosciences-apto-downgraded-by-zacks-investment-research-to-sell.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.